Clinical Screening of Epipodophyllotoxin VM26 in Malignant Lymphomas and Solid Tumours

doi:10.1136/bmj.2.5816.744

BMJ

1972

DOI: 10.1136/bmj.2.5816.744

|View full text |Cite

Clinical Screening of Epipodophyllotoxin VM26 in Malignant Lymphomas and Solid Tumours

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1974

1984

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 45 publications

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

4′-Demethyl-epipodophyllotoxin-β-D-thenylidene-glucoside (PTG) in the treatment of malignant intracranial neoplasms

Sklanskv

Kaplan²,

Reynolds³

et al. 1974

Cancer

View full text Add to dashboard Cite

Twenty evaluable patients, 19 with primary intracranial neoplasms, were treated with intravenous PTG at weekly doses of 100 mg/m2 to 130 mg/m2 in a Phase II study. A total of 63 courses (6–8 doses/course) was administered. Antineoplastic activity was demonstrated by objective neurologic improvement in 5 of 13 patients with progressive neurologic findings at the outset of therapy. Of the remaining 7 asymptomatic patients, there has been a median progression‐free interval of 15+ months, with 5 patients remaining on study. Anemia and mild leukopenia, the most frequent toxicities, were clinically insignificant in 12 previously untreated patients. Among 8 patients with extensive prior chemotherapy, pancytopenia required discontinuation of therapy in 1 and decreased frequency of administration in 2 others. PTG is presented as an effective drug, with minimal toxicity, for the treatment of intracranial neoplasms. It would appear to offer potential as an agent for Phase III trials as well as a mode of therapy for those patients no longer able to tolerate nitrosoureas, or with disease progression on nitrosoureas.

show abstract

4′-Demethyl-epipodophyllotoxin-β-D-thenylidene-glucoside (PTG) in the treatment of malignant intracranial neoplasms

Sklanskv

Kaplan²,

Reynolds³

et al. 1974

Cancer

View full text Add to dashboard Cite

show abstract

Two epipodophyllotoxin derivatives, VM 26 and VP 16213, in the treatment of leukemias, hematosarcomas, and lymphomas

Mathé

Schwarzenberg

Pouillart

et al. 1974

Cancer

111

View full text Add to dashboard Cite

VM 26 and VP 16–213: A comparative analysis

Rozencweig

Hoff

Henney

et al. 1977

Cancer

116

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Clinical Screening of Epipodophyllotoxin VM26 in Malignant Lymphomas and Solid Tumours

Cited by 45 publications

References 16 publications

4′-Demethyl-epipodophyllotoxin-β-D-thenylidene-glucoside (PTG) in the treatment of malignant intracranial neoplasms

4′-Demethyl-epipodophyllotoxin-β-D-thenylidene-glucoside (PTG) in the treatment of malignant intracranial neoplasms

Two epipodophyllotoxin derivatives, VM 26 and VP 16213, in the treatment of leukemias, hematosarcomas, and lymphomas

VM 26 and VP 16–213: A comparative analysis

Contact Info

Product

Resources

About